Navigation Links
Breckenridge Completes Acquisition of Certain Cypress Products from Pernix Therapeutics
Date:9/11/2013

BOCA RATON, Fla., Sept. 11, 2013 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has completed its acquisition of certain Cypress Pharmaceutical, Inc. product assets from Pernix Therapeutics. The assets include 11 Abbreviated New Drug Applications (ANDAs) filed with the FDA, certain ANDAs in various stages of development, as well as 6 already-approved and marketed products.  The company will begin distributing these Cypress-labeled products immediately, and the next phase will be converting these products to the Breckenridge label.  Customers have received detailed notices on the affected products and changes in ordering policies earlier today.

The assets include various unique dosage forms, such as ophthalmic, nasal spray, oral solution, syrup, and powder products, in addition to solid-oral products.  Breckenridge will begin marketing the approved products and continue to prosecute those ANDAs currently filed and pending with FDA.  "Breckenridge is excited to expand our current portfolio, as well as our R&D pipeline.  The Cypress assets are a natural fit to and complement the Breckenridge portfolio," stated Larry Lapila, Executive Vice President of Breckenridge Pharmaceutical, Inc. 

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories.  The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide.  The company markets over 70 products in a variety of dosage forms including:  Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions, and Powders.  www.bpirx.com


'/>"/>
SOURCE Breckenridge Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Breckenridge Announces Approval for Pioglitazone Hydrochloride tablets
2. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
3. Breckenridge Pharmaceutical signs Letter of Intent with Welding GmbH & Co & SK Chemicals
4. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
5. Breckenridge Enters Into Agreement to Acquire Certain Cypress Assets from Pernix Therapeutics
6. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
9. CryoLife Completes Acquisition of Hemosphere
10. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
11. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the third quarter of 2017. ... paid on or about October 27, 2017 to stockholders of ... 2017.  Future declarations of dividends are subject to approval of ...
Breaking Medicine Technology:
(Date:8/16/2017)... Bethpage, NY (PRWEB) , ... August 16, 2017 , ... ... Kullen, Long Island’s original family-owned supermarket, has put together suggestions for enjoying the season ... new recipe or activity, everyone in the family can join in on the fun. ...
(Date:8/16/2017)... ... ... August 3rd article on Reuters covers a new University of Michigan study on ... of the American Medical Association). The study found that a lower percentage of patients with ... to patients with lower BMIs. At present, weight loss patients must have a BMI of ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, ... that it was acquired by Advantage Solutions. The Data Council’s IX-ONE platform ... include the industry’s leading suppliers, brokers, distributors and retailers. The Data Council will ...
(Date:8/16/2017)... ... August 16, 2017 , ... In 1987, ... celebrate 30 years in business this year, and they’re marking the milestone by ... to serve their patients. , It stands to reason that, given the ...
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
Breaking Medicine News(10 mins):